A citation-based method for searching scientific literature

Matthias Scheffler, Marc Bos, Masyar Gardizi, Katharina König, Sebastian Michels, Jana Fassunke, Carina Heydt, Helen Künstlinger, Michaela Ihle, Frank Ueckeroth, Kerstin Albus, Monika Serke, Ulrich Gerigk, Wolfgang Schulte, Karin Töpelt, Lucia Nogova, Thomas Zander, Walburga Engel-Riedel, Erich Stoelben, Yon-Dschun Ko, Winfried Randerath, Britta Kaminsky, Jens Panse, Carolin Becker, Martin Hellmich, Sabine Merkelbach-Bruse, Lukas C Heukamp, Reinhard Büttner, Jürgen Wolf. Oncotarget 2015
Times Cited: 73







List of co-cited articles
444 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



PIK3CA mutations and copy number gains in human lung cancers.
Hiromasa Yamamoto, Hisayuki Shigematsu, Masaharu Nomura, William W Lockwood, Mitsuo Sato, Naoki Okumura, Junichi Soh, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong,[...]. Cancer Res 2008
325
16

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Lei Wang, Haichuan Hu, Yunjian Pan, Rui Wang, Yuan Li, Lei Shen, Yongfu Yu, Hang Li, Deng Cai, Yihua Sun,[...]. PLoS One 2014
121
15

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
12

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
12


Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
S Li, L Li, Y Zhu, C Huang, Y Qin, H Liu, L Ren-Heidenreich, B Shi, H Ren, X Chu,[...]. Br J Cancer 2014
155
12

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
10

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
10

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Jamie E Chaft, Maria E Arcila, Paul K Paik, Christopher Lau, Gregory J Riely, M Catherine Pietanza, Maureen F Zakowski, Valerie Rusch, Camelia S Sima, Marc Ladanyi,[...]. Mol Cancer Ther 2012
154
10

High frequency of mutations of the PIK3CA gene in human cancers.
Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi Gazdar, Steven M Powell, Gregory J Riggins,[...]. Science 2004
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
9

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Jeffrey A Engelman, Toru Mukohara, Kreshnik Zejnullahu, Eugene Lifshits, Ana M Borrás, Christopher-Michael Gale, George N Naumov, Beow Y Yeap, Emily Jarrell, Jason Sun,[...]. J Clin Invest 2006
373
9

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Jill M Spoerke, Carol O'Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K Brachmann, Peter M Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath,[...]. Clin Cancer Res 2012
130
9


EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
8

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
8

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
8

PIK3CA mutation status in Japanese lung cancer patients.
Osamu Kawano, Hidefumi Sasaki, Katsuhiko Endo, Eriko Suzuki, Hiroshi Haneda, Haruhiro Yukiue, Yoshihiro Kobayashi, Motoki Yano, Yoshitaka Fujii. Lung Cancer 2006
196
8

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
8


Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Juliana Eng, Kaitlin M Woo, Camelia S Sima, Andrew Plodkowski, Matthew D Hellmann, Jamie E Chaft, Mark G Kris, Maria E Arcila, Marc Ladanyi, Alexander Drilon. J Thorac Oncol 2015
66
9

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Lauren M Thorpe, Haluk Yuzugullu, Jean J Zhao. Nat Rev Cancer 2015
831
8

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
6

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Ji-Youn Han, Keunchil Park, Sang-We Kim, Dae Ho Lee, Hyae Young Kim, Heung Tae Kim, Myung Ju Ahn, Tak Yun, Jin Seok Ahn, Cheolwon Suh,[...]. J Clin Oncol 2012
608
6

Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio,[...]. N Engl J Med 2009
6

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
Binaifer R Balsara, Jianming Pei, Yasuhiro Mitsuuchi, Robert Page, Andres Klein-Szanto, Hao Wang, Michael Unger, Joseph R Testa. Carcinogenesis 2004
237
6

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
6

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
6

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
Jeffrey A Engelman, Ji Luo, Lewis C Cantley. Nat Rev Genet 2006
6

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Sohye Kang, Andreas G Bader, Peter K Vogt. Proc Natl Acad Sci U S A 2005
655
6

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
Marc McGowan, Aleksandra Silye Hoven, Marius Lund-Iversen, Steinar Solberg, Åslaug Helland, Fred R Hirsch, Odd Terje Brustugun. Lung Cancer 2017
20
25

PTEN and PI3K/AKT in non-small-cell lung cancer.
Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Miguel Ángel Molina, María José Faus-Dáder, Miguel Ángel Calleja-Hernández. Pharmacogenomics 2015
149
6

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Pasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Suresh S Ramalingam, Myung-Ju Ahn, Sang-We Kim, Wu-Chou Su, Leora Horn,[...]. N Engl J Med 2015
5

Acquired resistance to TKIs in solid tumours: learning from lung cancer.
D Ross Camidge, William Pao, Lecia V Sequist. Nat Rev Clin Oncol 2014
607
5

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
5

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
5

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
5

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
5

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
William Pao, Vincent Miller, Maureen Zakowski, Jennifer Doherty, Katerina Politi, Inderpal Sarkaria, Bhuvanesh Singh, Robert Heelan, Valerie Rusch, Lucinda Fulton,[...]. Proc Natl Acad Sci U S A 2004
5

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
5

Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
5

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
481
5

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
5

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
368
5

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Johan F Vansteenkiste, Jean-Luc Canon, Filippo De Braud, Francesco Grossi, Tommaso De Pas, Jhanelle E Gray, Wu-Chou Su, Enriqueta Felip, Hiroshige Yoshioka, Cesare Gridelli,[...]. J Thorac Oncol 2015
115
5

New targetable oncogenes in non-small-cell lung cancer.
Geoffrey R Oxnard, Adam Binder, Pasi A Jänne. J Clin Oncol 2013
245
5

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.